Skip to Content
  • Previous Rank
    17
  • Revenues ($M)
    $118,214.00
  • Revenue Percent Change
    0.7%
  • Profits ($M)
    $4,078.00
  • Profits Percent Change
    -2.3%
  • Assets ($M)
    $66,009.00
  • Employees
    290,000
  • Market Value — as of March 29, 2018 ($M)
    $64,924.30

In December Walgreen’s announced a 40% stake in Sinopharm Holding Guoda Drugstores in China, expanding the company’s global reach. And the pharma retailer is getting into the data game, having spent over $500 million to-date on updating pharmacy management and data collection system and turning its 88.6 million user “Balance Rewards” program into a customer insight tool. Despite these expansion efforts and stronger than expected Q2 earnings, shareholders have watched the pharma retailer’s share price drop 22% since January, largely due to Amazon’s plan to sell prescription drugs to doctors and hospitals.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
Stefano Pessina
CEO Title
Vice Chairman & Chief Executive Officer
Sector
Food & Drug Stores
Industry
Food and Drug Stores
HQ Location
Deerfield, Ill.
Websitehttp://www.walgreensbootsalliance.com
Years on Fortune 500 List24
Employees290,000
Figures are for fiscal year ended Aug. 31, 2017.

Walgreens Boots Alliance Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$118,214.000.7%
Profits ($M)$4,078.00-2.3%
Assets ($M)$66,009.00-
Total Stockholder Equity ($M)$27,466.00-
Market Value — as of March 29, 2018 ($M)$64,924.30-

Profit Ratios

Profit as % of Revenues3.4%
Profits as % of Assets6.2%
Profits as % of Stockholder Equity14.8%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)3.78
EPS % Change (from 2016)-1%
EPS % Change (5 year annual rate)9.3%
EPS % Change (10 year annual rate)6.4%

Total Return

Total Return to Investors (2017)-10.5%
Total Return to Investors (5 year, annualized)16.6%
Total Return to Investors (10 year, annualized)8.8%